drugset

drugset / Trial / NCT00062049

Interleukin-7 in Treating Patients With Refractory Solid Tumors

NCT00062049 ↗

Phase 1 Completed 30 enrolled National Institutes of Health Clinical Center (CC) National Cancer Institute (NCI) · collab

Treatment

Summary

RATIONALE: Interleukin-7 may stimulate a person's white blood cells to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-7 in treating patients with refractory solid tumors.

Timeline

Start: 2003-04
Primary completion: —
Completion: 2011-05

Publications

Results Sportes C, Babb RR, Krumlauf MC, Hakim FT, Steinberg SM, Chow CK, Brown MR, Fleisher TA, Noel P, Maric I, Stetler-Stevenson M, Engel J, Buffet R, Morre M, Amato RJ, Pecora A, Mackall CL, Gress RE. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res. 2010 Jan 15;16(2):727-35. doi: 10.1158/1078-0432.CCR-09-1303. Epub 2010 Jan 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Interleukin-7	Protein / enzyme biologic	3 ug/kg	Subcutaneous
Subject	Interleukin-7	Protein / enzyme biologic	10 ug/kg	Subcutaneous
Subject	Interleukin-7	Protein / enzyme biologic	30 ug/kg	Subcutaneous
Subject	Interleukin-7	Protein / enzyme biologic	60 ug/kg	Subcutaneous

Indications